Theratechnologies (NASDAQ:THTX) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Theratechnologies (NASDAQ:THTX) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.14), Zacks reports.

Theratechnologies Price Performance

Shares of THTX traded down $0.18 on Wednesday, reaching $1.64. The company’s stock had a trading volume of 102,246 shares, compared to its average volume of 106,274. The stock’s 50 day simple moving average is $1.75 and its two-hundred day simple moving average is $1.45. The stock has a market capitalization of $75.18 million, a P/E ratio of -16.35 and a beta of 1.26. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.18.

Analyst Ratings Changes

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Theratechnologies stock. Bank of America Corp DE lifted its stake in Theratechnologies Inc. (NASDAQ:THTX) by 1,416.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,487 shares of the company’s stock after purchasing an additional 15,400 shares during the period. Bank of America Corp DE’s holdings in Theratechnologies were worth $30,000 at the end of the most recent reporting period.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.